CG Roehrborn, P Siami, J Barkin, R Damião… - European urology, 2010 - Elsevier
BACKGROUND: Combination therapy with dutasteride and tamsulosin provides significantly greater benefit than either monotherapy for various patient-reported outcomes in men with …
Background: Benign prostatic hyperplasia (BPH) is often associated with enlargement of the prostate gland, lower urinary tract symptoms, decreased urinary flow and a reduced quality …
CG Roehrborn, J Barkin, P Siami, A Tubaro… - BJU …, 2011 - Wiley Online Library
What's known on the subject? and What does the study add? Treatment of benign prostatic hyperplasia (BPH) centres on two drug classes, 5α‐reductase inhibitors and α‐blockers. The …
A Levy, GP Samraj - Cleveland Clinic journal of medicine, 2007 - europepmc.org
Benign prostatic hyperplasia (BPH) is a clinical diagnosis. While BPH is a common cause of lower urinary tract symptoms (LUTS) in men, LUTS can signify a number of other disease …
Benign prostatic hyperplasia (BPH) represents a significant burden in ageing men due to frequently associated lower urinary tract symptoms (LUTS), which may impair quality of life …
Z Zhou, Y Cui, J Wu, R Ding, T Cai, Z Gao - BMC urology, 2019 - Springer
Background We performed a meta-analysis to confirm the efficacy and safety of the combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in …
M Marberger, R Harkaway, J de la Rosette - European urology, 2004 - Elsevier
As demographics change, with the elderly constituting an increasing proportion of the population, the prevalence of benign prostatic hyperplasia (BPH) is increasing, with a …
Objective To investigate whether a fixed‐dose combination (FDC) of 0.5 mg dutasteride and 0.4 mg tamsulosin is more effective than watchful waiting with protocol‐defined initiation of …
AL Burnett, AJ Wein - The Journal of urology, 2006 - Elsevier
PURPOSE: We reviewed recent literature and treatment guidelines regarding the prevalence, pathophysiology, and management of BPO related to BPH; and management of …